Literature DB >> 12055674

Reduced expression of PTEN correlates with breast cancer progression.

Shikha Bose1, Allison Crane, Hanina Hibshoosh, Mahesh Mansukhani, Lynn Sandweis, Ramon Parsons.   

Abstract

PTEN is a tumor-suppressor gene with phosphatase activity that is mutated in a variety of cancers. We analyzed a series of 34 invasive and 18 in situ breast cancers with known molecular status of the PTEN genotype using immunohistochemistry. Reduced PTEN protein expression was seen in 38% of invasive cancers and in 11% of in situ cancers. The frequency of reduced expression was highest in stage II and III cancers. Reduced expression also correlated with aneuploidy. In addition, in tumors with both in situ and invasive components, expression within the ductal carcinoma in situ portion tended to reflect the expression pattern of the invasive component. These data suggest that PTEN expression is frequently reduced in advanced breast cancers. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12055674     DOI: 10.1053/hupa.2002.124721

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  44 in total

Review 1.  DNA methylation-based variation between human populations.

Authors:  Farzeen Kader; Meenu Ghai
Journal:  Mol Genet Genomics       Date:  2016-11-04       Impact factor: 3.291

2.  Combination of zoledronic acid and serine/threonine phosphatase inhibitors induces synergistic cytotoxicity and apoptosis in human breast cancer cells via inhibition of PI3K/Akt pathway.

Authors:  Zeki Surmeli; Pinar Gursoy; Atike Pinar Erdogan; Emir Bozkurt; Harika Atmaca; Selim Uzunoglu; Canfeza Sezgin; Ulus Ali Şanlı; Ruchan Uslu; Burcak Karaca
Journal:  Tumour Biol       Date:  2015-10-13

3.  Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma.

Authors:  Rita A Sakr; Violetta Barbashina; Mary Morrogh; Sarat Chandarlapaty; Victor P Andrade; Crispinita D Arroyo; Narciso Olvera; Tari A King
Journal:  Appl Immunohistochem Mol Morphol       Date:  2010-07

4.  Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells.

Authors:  Linda S Steelman; Patrick Navolanic; William H Chappell; Stephen L Abrams; Ellis W T Wong; Alberto M Martelli; Lucio Cocco; Franca Stivala; Massimo Libra; Ferdinando Nicoletti; Lyudmyla B Drobot; Richard A Franklin; James A McCubrey
Journal:  Cell Cycle       Date:  2011-09-01       Impact factor: 4.534

5.  MicroRNA-143 is downregulated in breast cancer and regulates DNA methyltransferases 3A in breast cancer cells.

Authors:  Enders K O Ng; Rufina Li; Vivian Y Shin; Jennifer M Siu; Edmond S K Ma; Ava Kwong
Journal:  Tumour Biol       Date:  2013-11-13

6.  KDM5B Is Essential for the Hyperactivation of PI3K/AKT Signaling in Prostate Tumorigenesis.

Authors:  Guoliang Li; Thanigaivelan Kanagasabai; Wenfu Lu; Mike R Zou; Shang-Min Zhang; Sherly I Celada; Michael G Izban; Qi Liu; Tao Lu; Billy R Ballard; Xinchun Zhou; Samuel E Adunyah; Robert J Matusik; Qin Yan; Zhenbang Chen
Journal:  Cancer Res       Date:  2020-08-31       Impact factor: 12.701

7.  Deubiquitylase OTUD3 regulates PTEN stability and suppresses tumorigenesis.

Authors:  Lin Yuan; Yanrong Lv; Hongchang Li; Haidong Gao; Shanshan Song; Yuan Zhang; Guichun Xing; Xiangzhen Kong; Lijing Wang; Yang Li; Tao Zhou; Daming Gao; Zhi-Xiong Xiao; Yuxin Yin; Wenyi Wei; Fuchu He; Lingqiang Zhang
Journal:  Nat Cell Biol       Date:  2015-08-17       Impact factor: 28.824

Review 8.  Targeting the function of the HER2 oncogene in human cancer therapeutics.

Authors:  M M Moasser
Journal:  Oncogene       Date:  2007-05-07       Impact factor: 9.867

9.  Sequestosome 1/p62 facilitates HER2-induced mammary tumorigenesis through multiple signaling pathways.

Authors:  X Cai-McRae; H Zhong; V Karantza
Journal:  Oncogene       Date:  2014-08-04       Impact factor: 9.867

10.  Altered PTEN expression; a diagnostic marker for differentiating normal, hyperplastic and neoplastic endometrium.

Authors:  Soheila Sarmadi; Narges Izadi-Mood; Kambiz Sotoudeh; Seyed Mohammad Tavangar
Journal:  Diagn Pathol       Date:  2009-11-25       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.